here the "latest news" from JOMED's website (reminder: ESON and JOMED are to develop together a combined IVUS-stent approach)
JOMED experiences record growth
JOMED AB, with sales in 45 countries and active in interventional cardiology, interventional radiology and minimally invasive cardiac assist is one of the fastest growing european companies in minimally invasive care.
JOMED, the Swedish-German company, has announced significantly increased sales and earnings for the first six months of 1998. Sales more than doubled from DM 12 million to DM 25.5 million, as did net income, which increased from DM 3,2 million to DM 7,5 million. The increase is substantially due to significantly increased volumes and the set up of direct sales organisations in several European markets.
The company's unique range of JOSTENT coronary and peripheral stents has made major inroads in several European and international markets. According to JOMED, the company has positioned itself as the fast innovator in interventional cardiology, succeeding in bringing innovation to the market faster and more successfully than most competitors. Heavy investments in R&D have led to a number of unique and successful products like specially designed stents, allowing stenting of stenoses at side branches or bifurcations and the first coronary PFTE covered stent, the JOSTENT Coronary Stent Graft.
According to Tor Peters, President and CEO, "JOMED delivered some 35,000 stents to the market in 1997. In 1998 the company is increasing this substantially and looks forward to several new innovative products like our range of Nitinol stents and the new minimally-invasive cardiac assist system, the JOMED CatheterPump." JOMED expects to continue its high rate of growth over the next several years, and 12 month result for 1998 are likely to reflect this continued expansion. |
